ANEB - NASDAQ

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%

HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$70.67M

EPS-0.2500

P/E Ratio-5.74

Earnings Date02/12/2026

aneb

Total Current Liabilities

Last Annual Value

224.18K

3-Year CAGR

-24%

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Total Current Liabilities

ANEB · NASDAQ

Company	Total Current Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Anebulo Pharmaceuticals, Inc. NASDAQ:ANEB	224.18K	-25.1%	-1.5%	N/A
Clene Inc. NASDAQ:CLNN	10.78M	-24.8%	12.3%	N/A
Immix Biopharma, Inc. NASDAQ:IMMX	10.11M	39.5%	118.7%	N/A
Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL	36.56M	-19.2%	-3.6%	N/A
aTyr Pharma, Inc. NASDAQ:ATYR	15.15M	-2.6%	20.3%	5.9%
Biomea Fusion, Inc. NASDAQ:BMEA	11.10M	-21.4%	19.1%	N/A
eXoZymes, Inc. NASDAQ:EXOZ	1.57M	-13.4%	31.3%	N/A
Fractyl Health, Inc. Common Stock NASDAQ:GUTS	18.33M	17.9%	-5.0%	N/A
Oramed Pharmaceuticals Inc. NASDAQ:ORMP	19.09M	-29.0%	23.4%	18.1%
Quince Therapeutics, Inc. NASDAQ:QNCX	7.28M	-8.7%	-12.5%	N/A
Spruce Biosciences, Inc. NASDAQ:SPRB	10.09M	-25.6%	2.6%	N/A

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.72

Related Guides

Blog Categories

Continue your ANEB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.